首页> 外文期刊>European journal of gastroenterology and hepatology >Long-term efficacy of hepatitis B vaccination in healthcare workers of Oil Company Hospital, Tehran, Iran (1989-2005).
【24h】

Long-term efficacy of hepatitis B vaccination in healthcare workers of Oil Company Hospital, Tehran, Iran (1989-2005).

机译:伊朗德黑兰石油公司医院医护人员的乙肝疫苗接种长期效果(1989-2005年)。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: This study was conducted to evaluate the 16-year efficacy of hepatitis B virus (HBV) vaccine in healthcare workers of Oil Company Hospital, Tehran, Iran. METHODS: Two hundred healthcare workers were enrolled in the study in 1989. All HBV markers were tested and those with positive HBV markers, positive antihepatitis C virus or anti-HIV were excluded from the study. The remaining participants received three doses of HBV vaccine and again all of our participants were reevaluated in 2005. Hepatitis B surface antigen (HBsAg), antihepatitis B surface antibody (anti-HBsAb), and antihepatitis B core antibody (anti-HBcAb) were checked in all participants and those with anti-HBcAb above 10 IU/l were excluded from the final evaluation. RESULTS: No participant was positive for HBsAg in either 1989 or 2005. Protective levels of anti-HBsAb were absent in all participants in 1989, but present in 67 (80.7%) participants in 2005 (P<0.001). Anti-HBsAb titer after vaccination was significantly higher in female participants than in male participants (P=0.01). Mean anti-HBsAb titer was 640+/-411.7 IU/l (range: 2-1000 IU/l) and the lowest protective titer was 12 IU/l. CONCLUSION: According to our results, 80.7% of our participants had a protective titer of anti-HBsAb 16 years after vaccination. Although all anti-HBc positive participants were free of clinical hepatitis and were negative for HBsAg, hepatitis B vaccination was proved to be highly effective in preventing clinically significant infection and chronic carrier status up to 16 years after the primary vaccination. Hence, HBV revaccination may not be mandatory in healthcare workers, according to their sufficient long-term level of anti-HBsAb.
机译:目的:本研究旨在评估乙型肝炎病毒(HBV)疫苗在伊朗德黑兰石油公司医院医护人员中的16年疗效。方法:1989年,该研究招募了200名医护人员。所有HBV标志物均经过测试,而HBV标志物阳性,抗丙型肝炎病毒或抗HIV阳性的人被排除在研究之外。其余的参与者接受了三剂HBV疫苗,我们的所有参与者在2005年再次进行了重新评估。检查了乙型肝炎表面抗原(HBsAg),抗乙型肝炎表面抗体(anti-HBsAb)和抗乙型肝炎核心抗体(anti-HBcAb)在所有参与者中,抗-HBcAb高于10 IU / l的参与者均未纳入最终评估。结果:在1989年或2005年,没有受试者HBsAg阳性。1989年所有受试者中均未存在抗HBsAb的保护水平,但在2005年有67名(80.7%)受试者中存在(P <0.001)。接种疫苗后女性参与者的抗HBsAb滴度明显高于男性参与者(P = 0.01)。平均抗HBsAb滴度为640 +/- 411.7 IU / l(范围:2-1000 IU / l),最低保护性滴度为12 IU / l。结论:根据我们的研究结果,接种疫苗16年后,有80.7%的参与者具有抗HBsAb的保护性滴度。尽管所有抗HBc阳性参与者均无临床肝炎且HBsAg阴性,但事实证明,在初次接种疫苗后的16年内,乙肝疫苗接种可有效预防临床上的重大感染和慢性携带者感染。因此,根据医护人员的长期抗-HBsAb水平,他们可能不一定要重新接种HBV。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号